Abstract:Background and Objectives: The microbiota-gut-brain axis has been suggested to play an important role in synucleinopathy. Microbiota dysbiosis may occur in synucleinopathies including multiple system atrophy (MSA) and Parkinson’s disease (PD), however, the results of the microbiota were heterogeneous. Here we performed a cross-sectional study to profile gut microbiota across Idiopathic rapid-eye-movement sleep behavior disorder (iRBD), MSA, PD, and healthy controls (HCs) using multimodal differential abundance analyses based on DADA2 denoising algorithm and operational taxonomic unit (OTU) clustering method. Methods Gut microbiota and fecal Short-chain fatty acids (SCFAs) levels were measured in 37 iRBD, 70 MSA, 104 PD, and 61 HCs matched by age, gender and BMI, using 16S rRNA sequencing and gas chromatography-mass spectrometry respectively. Additionally, the samples were divided into training set and testing set to ensure robustness in our findings. Results Gut microbiota compositions were significantly altered in iRBD, MSA, and PD. The increase in the abundance of pro-inflammatory bacteria and decrease in the abundance of SCFA-Producing bacteria were observed in iRBD, MSA, and PD. Butyricicoccus remained distinctive among the overlapping gut microbiota genera of iRBD, MSA, and PD compared to HCs as revealed by random forest analysis. The fecal SCFAs levels (acetic acid, butyric acid, and isovaleric acid) were also altered in iRBD, MSA, and PD. The combination of differential microbiota and SCFAs could improve the accuracy of predictive models in the diagnosis and differential diagnosis of synucleinopathies. Conclusions Microbiota dysbiosis was observed in iRBD, sharing overlapping gut microbiota changes with synucleinopathies, indicating microbiota dysbiosis might be an early change in the disease process of synucleinopathies. Consequent functional alterations, such as SCFA changes, may provide microbiological explanations for pathogenesis of synucleinopathy. We identified Butyricicoccus as a biomarker for synucleinopathy, sharing by iRBD, MSA and PD, which may be a potential hallmark of phenoconversion of RBD to synucleinopathy. The combination of microbiota and SCFAs may be potential biomarkers in the diagnosis and differential diagnosis of synucleinopathies.

α-Synuclein Overexpression and the Microbiome Shape the Gut and Brain Metabolome in Mice

Alpha-synuclein overexpression can drive microbiome dysbiosis in mice

The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson's disease mouse model

Altered Gut Microbiome in Parkinson’s Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model

A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice

Altered Actinobacteria and Firmicutes Phylum Associated Epitopes in Patients With Parkinson's Disease

Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease

Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson disease

Oral, Nasal, and Gut Microbiota in Parkinson's Disease.

Gut Microbiota and Metabolites of Α-Synuclein Transgenic Monkey Models with Early Stage of Parkinson’s Disease

Changes in Gastrointestinal Microbiome Composition in PD: A Pivotal Role of Covariates

Gut microbiota and metabolites of α-synuclein transgenic monkey models with early stage of Parkinson'sdisease

Gut microbiota dysbiosis contributes to α-synuclein-related pathology associated with C/EBPβ/AEP signaling activation in a mouse model of Parkinson's disease

The Impact of Intestinal Microbiota and Toll-like Receptor 2 Signaling on α-Synuclein Pathology in Nontransgenic Mice Injected with α-Synuclein Preformed Fibrils

Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status

Compositional changes in fecal microbiota in a new Parkinson's disease model: C57BL/6-Tg(NSE-haSyn) mice

Altered Gut Microbiome and Metabolism in Synucleinopathies and Irbd Using Multimodal Differential Abundance Analyses

Gut-induced alpha-Synuclein and Tau propagation initiate Parkinson's and Alzheimer's disease co-pathology and behavior impairments

Multiomics of parkinsonism cynomolgus monkeys highlights significance of metabolites in interaction between host and microbiota

Norepinephrine depleting toxin DSP-4 and LPS alter gut microbiota and induce neurotoxicity in α-synuclein mutant mice

Gut-induced Alpha-Synuclein and Tau Propagation Initiate Parkinson’s and Alzheimer’s Disease Co-Pathology and Behavior Impairments